Sign in

NCT07815093Not yet recruiting

Multimodal Artificial Intelligence for Non-Invasive Colorectal Cancer Screening Based on Holographic Biology

Multimodal Artificial Intelligence for Non-Invasive Colorectal Cancer Screening Based on Holographic Biology.

Source: ClinicalTrials.gov · Last updated 11 Sept 2026

Brief summary (registry, in English)

The purpose of this study is to propose a non-invasive screening method by integrating holographic biological theory and artificial intelligence technology. A colorectal cancer risk assessment model will be constructed by analyzing multimodal data including facial features, tongue image characteristics and exhaled gas. The hypothesis of this study is that the model can attain both sensitivity and specificity of 80%.This study will enroll patients aged 18-80 years scheduled to undergo colonoscopy. All participants shall provide informed consent and sign the informed consent form. Patients will be excluded if they have severe cardiac, cerebral, pulmonary or renal dysfunction, or psychiatric disorders precluding colonoscopy, have a history of gastrointestinal surgery, or have taken bismuth agents or other staining medications. Based on estimates from existing literature, the training set will require tongue images, facial images, exhaled gas analysis results and colonoscopic diagnoses from 5000 patients, and the test set will require such data from 6000 patients.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
11000 (estimated)
First submitted
6 Sept 2026
Start date
1 Oct 2026
Primary completion date
1 Apr 2028
Lead sponsor
Xiuli Zuo
NCT number
NCT07815093

What you commit to

  • Study type: Observational
  • Planned participants: 11000
  • From 1 Oct 2026 to the primary completion date, 1 Apr 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients taking bismuth agents or other staining medications.

Other illness

  • Patients with severe cardiac, cerebral, pulmonary or renal dysfunction, or psychiatric disorders that prevent colonoscopy;
  • Patients with a history of gastrointestinal surgery;

Who the study is looking for

  • Patients aged 18-80 years scheduled to undergo colonoscopy.
  • All patients provide informed consent and sign the informed consent form.

Age in the registry: 18 years to 80 years · Sex: All

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.